Zurich, Switzerland, September 15th, 2026, FinanceWire
With total seed funding now exceeding USD 14 million, the strategic acquisition of Germany's leading consumer blood diagnostics platform positions Aeon as the category-defining company combining whole-body imaging, recurring blood diagnostics, and AI-driven risk prediction.
Aeon, the preventive healthcare company pioneering AI-powered whole-body health check-ups, today announces the close of its seed extension and the acquisition of the core assets of Aware Health, Germany's leading consumer blood diagnostics platform. Aeon is now the first European platform to offer a continuous, longitudinal health picture, combining whole-body imaging with recurring blood diagnostics in a single product, with AI turning that data into personalised risk prediction.
This seed extension brings Aeon's total seed funding to over USD 14 million. The extension was co-led by Araya Ventures with participation from existing investors Concentric, GoHub Ventures, Kadmos Capital, Calm/Storm Ventures, N&V Capital, and Bigwave Capital, and funds the integration of Aware Health's technology and team alongside Aeon's accelerated European roadmap.
From Detect...